Tumor Markers in Lung Cancer: DCAMLK-1LK-1: A Pilot Study
45 Years
N/A
Both
Lung Cancer, Smoking
Trial Information
Tumor Markers in Lung Cancer: DCAMLK-1LK-1: A Pilot Study
In the investigators' preliminary study DCAMKL1 antigen was detected not only in malignant
tissue, but also in BAL fluid from patients with benign lung disease. This suggests that
DCAMKL1 expression might be induced by smoking or benign lung diseases. To examine this
hypothesis, the investigators will compare DCAMLK1 expression in blood from patients with
lung cancer to controls who are current or former smokers with benign lung disease.
Previous work has showed that DCAMLK1 is not detectable in the blood of healthy non smoking
individuals. To determine whether smoking and or pulmonary inflammation induce DCAMLK1
expression, the investigators will obtain serum samples from 20 control patients with lung
disease who are seen in the Chest Clinic at the Oklahoma City VAMC. Smoking histories will
be obtained for all participants and DCAMLK1 levels will be correlated with smoking status.
Inclusion Criteria:
- >45 years of age
Exclusion Criteria:
- Unable to provide informed consent
Type of Study:
Interventional
Study Design:
Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic
Outcome Measure:
Tumor Markers in Lung Cancer:
Outcome Description:
DCAMLK-1LK-1 levels will be measured in the blood of patients with Lung Cancer and compared to that of controls with other lung diseases.
Outcome Time Frame:
6 months
Safety Issue:
No
Principal Investigator
Kellie Jones, MD
Investigator Role:
Principal Investigator
Investigator Affiliation:
University of Oklahoma
Authority:
United States: Institutional Review Board
Study ID:
16249
NCT ID:
NCT01578018
Start Date:
December 2011
Completion Date:
July 2012
Related Keywords:
- Lung Cancer
- Smoking
- lung cancer
- smoking
- Lung Neoplasms
- Smoking
Name | Location |
|---|---|
| VAMC-OKC | Oklahoma City, Oklahoma 73104 |
